SeaStar Medical - חוב כולל להון ICU

SeaStar Medical Holding (ICU) develops innovative blood purification systems. The asset's market valuation dynamics, currently 0.03, correlate with the implementation of eco-friendly materials and the reduction of plastics in production. The company relies on a compact staff of scientists and the strategic hiring of top managers for trials. The business generates revenue through the continuous sale of replacement components for installed devices, ensuring high profitability.

Defensive assets are selected based on minimum insolvency risk, which is critical for SeaStar Medical Holding (ICU) until insurance reimbursements for FDA-approved devices are fully implemented. This debt-to-equity ratio measures the degree of leverage, comparing total liabilities to equity to assess the stability of the WACC structure and the company's ability to service loans while establishing pricing power.